HC Wainwright Equities Analysts Reduce Earnings Estimates for BioNTech SE (NASDAQ:BNTX)

BioNTech SE (NASDAQ:BNTX) – Equities researchers at HC Wainwright reduced their FY2024 EPS estimates for shares of BioNTech in a research note issued on Tuesday, August 27th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($3.71) per share for the year, down from their previous forecast of ($3.66). HC Wainwright has a “Buy” rating and a $113.00 price objective on the stock. The consensus estimate for BioNTech’s current full-year earnings is ($2.04) per share. HC Wainwright also issued estimates for BioNTech’s Q1 2025 earnings at ($2.39) EPS, Q2 2025 earnings at ($2.40) EPS and FY2025 earnings at ($3.15) EPS.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, August 5th. The company reported ($3.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). BioNTech had a net margin of 4.01% and a return on equity of 0.55%. The company had revenue of $128.70 million during the quarter, compared to analysts’ expectations of $134.98 million. During the same period last year, the firm earned ($0.86) earnings per share. BioNTech’s revenue was down 23.3% on a year-over-year basis.

Other equities analysts also recently issued reports about the company. TD Cowen cut their target price on BioNTech from $98.00 to $85.00 and set a “hold” rating for the company in a research note on Tuesday, August 6th. Evercore ISI initiated coverage on shares of BioNTech in a research report on Tuesday, May 14th. They set an “inline” rating and a $100.00 target price on the stock. BMO Capital Markets cut their price target on shares of BioNTech from $123.00 to $122.00 and set an “outperform” rating for the company in a report on Tuesday, May 7th. HSBC raised shares of BioNTech from a “hold” rating to a “buy” rating in a report on Friday, August 2nd. Finally, Deutsche Bank Aktiengesellschaft raised shares of BioNTech from a “hold” rating to a “buy” rating and set a $95.00 price objective for the company in a research note on Wednesday, August 7th. One analyst has rated the stock with a sell rating, five have given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $109.09.

BioNTech Trading Up 1.3 %

NASDAQ BNTX opened at $88.20 on Thursday. BioNTech has a 52-week low of $76.53 and a 52-week high of $125.83. The firm has a 50-day moving average price of $83.92 and a 200 day moving average price of $89.39. The stock has a market capitalization of $20.97 billion, a P/E ratio of 176.40 and a beta of 0.23. The company has a quick ratio of 11.16, a current ratio of 11.38 and a debt-to-equity ratio of 0.01.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of BNTX. GAMMA Investing LLC increased its stake in BioNTech by 121.0% in the first quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock valued at $25,000 after purchasing an additional 150 shares during the last quarter. CWM LLC increased its holdings in shares of BioNTech by 657.6% during the 4th quarter. CWM LLC now owns 250 shares of the company’s stock worth $26,000 after buying an additional 217 shares during the last quarter. Frazier Financial Advisors LLC purchased a new position in shares of BioNTech in the 4th quarter worth $30,000. First Horizon Advisors Inc. acquired a new stake in BioNTech during the fourth quarter worth about $38,000. Finally, Covestor Ltd increased its stake in BioNTech by 47.2% during the first quarter. Covestor Ltd now owns 415 shares of the company’s stock worth $38,000 after acquiring an additional 133 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.